Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored sound waves may sharpen the mind

NCT ID NCT07690865

Symptom relief Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether listening to a personalized sound frequency (in the gamma brainwave range) for one hour a day can improve cognitive function and brain synchronization. Twenty healthy adults will compare their optimal frequency against a non-optimal one over one-month periods. The goal is to see if tailoring the sound to each person works better than a one-size-fits-all approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized gamma auditory frequency stimulation via mobile app
What this could lead to
If it works, this could point toward a non-invasive, at-home method to enhance memory and thinking skills in healthy people.
What could go wrong
This is a small early-stage study with only 20 participants, so results may not apply widely. The effect may be small or not noticeable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 to 40 years old. 2. The Cognitive Abilities Screening Instrument (CASI) score is within normal ranges adjusted for age and education. 3. Participants have no history of severe neurological or psychiatric disorders (such as stroke, epilepsy, depression, migraine, etc.) that could affect cognitive function. 4. Participants have not used drugs that may affect cognitive function (e.g., benzodiazepines, anticholinergic medications, etc.). 5. Participants with normal or corrected vision (e.g., glasses or contact lenses) to normal levels. 6. Auditory stimuli induce significant neural entrainment. 7. Self-reported normal hearing Exclusion Criteria: 1. Participants enrolled in any cognitive enhancement study within the past two months. 2. Participants with a history of disease that could affect cognitive function (e.g., cancer, autoimmune diseases, etc.). 3. Individuals with tinnitus or hyperacusis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease(AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease(AD) Gamma entrainment using sensory stimuli (genus) Gamma oscillations Gamma oscillations; healthy adults; Alzheimer's disease (AD); gamma entrainment using sensory stimuli (genus) Healthy adults

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chang Gung University

    Taoyuan, Guishan, 33302, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.